TerrAscend (TSNDF) Cash from Financing Activities (2021 - 2026)
TerrAscend (TSNDF) posted quarterly Cash from Financing Activities of -$7.1 million for Q1 2026, down 205.44% year-over-year from $6.8 million in Q1 2025, and down 22.63% quarter-over-quarter from -$5.8 million in Q4 2025.
TerrAscend (TSNDF) Cash from Financing Activities (2021 - 2026) Analysis & Trends
TerrAscend (TSNDF) has reported Cash from Financing Activities for 6 consecutive years, with -$7.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 205.44% year-over-year to -$7.1 million; the TTM figure through Mar 2026 stood at -$609000.0 (up 96.51% YoY), while the FY2025 annual figure was $4.2 million, up 116.94% from the prior year.
- Cash from Financing Activities slipped to -$7.1 million in Q1 2026 per TSNDF's latest filing, from -$5.8 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $17.1 million in Q1 2022 and bottomed at -$15.1 million in Q4 2023.
- Historically, Cash from Financing Activities has averaged -$2.1 million across 5 years, with a median of -$4.4 million in 2024.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities slumped 728.16% — and 2025, when it jumped 283.0%.
- TerrAscend's Cash from Financing Activities stood at -$1.8 million in 2022, then plunged by 728.16% to -$15.1 million in 2023, then jumped by 70.78% to -$4.4 million in 2024, then tumbled by 32.18% to -$5.8 million in 2025, then dropped by 22.63% to -$7.1 million in 2026.
- Business Quant data shows TSNDF's Cash from Financing Activities at -$7.1 million in Q1 2026, -$5.8 million in Q4 2025, and $9.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | TerrAscend | 182.53 Mn | 140.41 Mn | 36.25 Mn | -1.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.90 Mn |
| Jun 30, 2026 | -1.90 Mn |
| Mar 31, 2026 | -7.13 Mn |
| Mar 31, 2026 | -7.13 Mn |
| Dec 31, 2025 | -5.82 Mn |
| Dec 31, 2025 | -5.82 Mn |
| Sep 30, 2025 | 9.72 Mn |
| Sep 30, 2025 | 9.72 Mn |
| Jun 30, 2025 | 2.62 Mn |
| Jun 30, 2025 | 2.62 Mn |
| Mar 31, 2025 | -2.34 Mn |
| Mar 31, 2025 | -2.34 Mn |
| Dec 31, 2024 | -4.40 Mn |
| Dec 31, 2024 | -4.40 Mn |
| Sep 30, 2024 | -5.31 Mn |
| Sep 30, 2024 | -5.31 Mn |
| Jun 30, 2024 | -5.41 Mn |
| Jun 30, 2024 | -5.41 Mn |
| Mar 31, 2024 | -9.60 Mn |
| Mar 31, 2024 | -9.60 Mn |